Equities research analysts forecast that VERONA PHARMA P/S (NASDAQ:VRNA) will announce ($0.49) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for VERONA PHARMA P/S’s earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.57). VERONA PHARMA P/S posted earnings of ($0.91) per share in the same quarter last year, which would indicate a positive year over year growth rate of 46.2%. The firm is scheduled to issue its next earnings results on Tuesday, November 6th.

Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for VERONA PHARMA P/S.

VERONA PHARMA P/S (NASDAQ:VRNA) last issued its quarterly earnings data on Tuesday, August 7th. The company reported $0.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.14) by $1.20.

VRNA has been the subject of several research analyst reports. Zacks Investment Research raised VERONA PHARMA P/S from a “hold” rating to a “strong-buy” rating and set a $14.00 price objective for the company in a report on Friday, August 24th. Wedbush reiterated a “buy” rating and set a $56.00 target price on shares of VERONA PHARMA P/S in a research report on Wednesday, September 19th. Jefferies Financial Group reiterated a “buy” rating and set a $26.00 target price on shares of VERONA PHARMA P/S in a research report on Friday, August 10th. Finally, ValuEngine downgraded VERONA PHARMA P/S from a “buy” rating to a “hold” rating in a research report on Monday, July 2nd. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. VERONA PHARMA P/S has a consensus rating of “Buy” and a consensus price target of $31.33.

Shares of VRNA opened at $11.75 on Wednesday. VERONA PHARMA P/S has a one year low of $10.44 and a one year high of $25.55. The firm has a market capitalization of $158.18 million, a P/E ratio of -4.88 and a beta of -2.82.


Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.

Recommended Story: Risk Tolerance and Your Investment Decisions

Get a free copy of the Zacks research report on VERONA PHARMA P/S (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VERONA PHARMA P/S (NASDAQ:VRNA)

Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.